Antihypertensive Drugs Market Research Report - Global Forecast to 2027

Global Antihypertensive Drugs Market Research Report: By Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others) - Forecast till 2027

ID: MRFR/Pharma/1731-CR | January 2019 | Region: Global | 124 pages

Please note that the assessment period of report has been updated from 2018-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Overview


The Antihypertensive Drugs Market size can touch USD 41,123.2 Million by 2023, according to the extensive research conducted by Market Research Future (MRFR). MRFR identifies the rising number of awareness campaigns by governmental and non-profit organizations across the world as one of the reasons for market growth.


COVID-19 Analysis


Antihypertensive drugs market share has declined owing to the lockdown imposed following the COVID-19 outbreak. The novel coronavirus pandemic has reduced the number of cardiac surgeries in view of the re-scheduling, no-show by patients, cancellations and lower consultations in the wake of restrictions by health authorities and government. In view of the steadily growing number of SARS-CoV-2 cases, only emergency services are currently being allowed, while the decrease in heart disease hospital admissions has slowed down the market growth.


However, MRFR experts believe that the market could be resilient over the forthcoming period. This can be the case since latest studies show that COVID-19 patients are dealing with sevaerl cardiovascular complications, and as a result, health authorities are encouraging the use of CVD drugs and antihypertensive drugs. This could ensure sustainable market growth in the years to follow. Surging popularity of e-commerce and online drug stores will also result in market expansion during the review period, despite the escalating novel coronavirus cases.


Market Dynamics


Drivers


Escalating Hypertension Cases Worldwide to Push Market Growth


One of the foremost growth rendering factors in the global market is the alarming rise in incidences of hypertension across countries. The growing cases are also raising the awareness level among the mass about the complications related to hypertension, which also encourages market growth. The consistently expanding geriatric pool across the globe along with the high prevalence of sedentary lifestyle fosters major growth as well. The mounting need for early diagnosis as well as treatment of hypertension is bolstering the demand for antihypertensive drugs in the market. Some of the modern anti-hypertensive drugs in the market that are used for treatment include ACE inhibitors, vasodilators and diuretics. However, these antihypertensive drugs in pregnancy are advised to be avoided so as not to give way to any complications.


Opportunities


Rising Preference for Combination Therapy to Offer Opportunities


Of late, combination therapies have witnessed significant applications compared to the monotherapy form of treatment. Monotherapy involves the use of a single drug, whereas combination therapy facilitates action on multiple hypertensive mechanisms. The latter involves combining two drugs that have varying mechanisms of action, which leads to an effect that is much higher than monotherapy.


Combination therapy helps bring down cerebrovascular events by 54% and coronary issues by 40%. Therefore, combination therapy offers better protection to the organ with lower dose compared to monotherapy and its wide acceptance across the world is proving to be a lucrative opportunity for leading firms in the global industry.


Restraints


Lower Awareness Levels in Developing Countries to be a Key Restraint


Lower awareness levels with regard to antihypertensive drugs amongst the mass in developing countries can be a huge restraint in the worldwide market. A vast population in developing countries tends to neglect health-checkups and has low knowledge about hypertension conditions and symptoms, which is making it hard for players to gain any profits in these regions.


Challenges


Patients with hypertension generally do not adhere to the required medication schedule and tend to stop medications in only 1 to 2 weeks, which gives rise to the symptoms again. This passive attitude of patients is posing a significant challenge to the firms in the anti-hypertensive drugs industry. For instance, in 2016, BMC Research conducted a research that stated that only 17% of 112 hypertensive individuals with stroke adhered to antihypertensive drugs and medications.


Cumulative Growth Analysis


Introduction of New Treatment Options to Bolster Market’s Growth Rate


The global antihypertensive drugs market growth is expected to be at a rate of 2.67% over the analysis period (between 2015 and 2023), on account of the rising introduction of new antihypertensive therapy options.


Segment Overview


Cost Effectiveness to Bolster Demand for Beta Blockers


MRFR’s review of anti-hypertensive drugs market outlines a few key therapeutic classes, namely beta-adrenergic blockers, calcium channel blockers, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, renin inhibitors, diuretics, vasodilators, and others. Latest studies have concluded that antihypertensive drugs beta blockers and diuretics are far more cost-effective compared to other therapeutic classes and therefore, observe considerable demand in the global market.


Secondary Hypertension-Based Drugs to observe Strong demand


Depending on the type of anti-hypertensive drugs in the market are primary as well as secondary. Secondary hypertension segment is in the lead owing to early diagnosis, faster detection, surging cases of thyroid problems, chronic alcohol use, kidney problems, heart ailments, adrenal gland tumors and more. However, the antihypertensive drugs classification by MRFR also reveals that the segmental growth can be slowed down by patent expiries including United Therapeutic's Remodulin (2014) and Actelion's Tracleer (2015).


E-Commerce Websites and Online Drug Stores Gain Massive Popularity


Distribution channels highlighted in the MRFR study are retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others. E-commerce websites and online drug stores segment can expect to surge forward at the fastest rate over the evaluation period, on account of the high internet usage and popularity of smartphones and tablets.


Regional Analysis


America to Reach the Leading Position in the Coming Years


AHA or American heart association claims that close to 74.9% of the total hypertension patients in North America are being treated while only about 52.2% of them have it under control. AHA also projects that by the year 2030; roughly 41.4% of individuals in the US/United States will suffer from hypertension. These scaling numbers indicate the bright growth prospects of the American market for antihypertensive drugs. Also, the mounting need for accurate and prompt diagnosis as well as treatment of hypertension, detecting people that are predisposed to the disorder and the presence of modern healthcare infrastructure also work in favor of the American anti-hypertension industry. The orthostatic hypotension drugs market has been growing exponentially in the region, with a soaring number of patients suffering from low blood pressure.


APAC Races Ahead at the Fastest Rate as China and India Take the Lead


MRFR anticipates the APAC market to exhibit the fastest growth during the conjectured period, thanks to the soaring awareness level about antihypertensive drugs and other treatment options. The stunning growth of the life science industry in India, Malaysia and China has also been an important growth booster in the APAC market. The anti-hypertensive drugs rhabdomyolysis are gaining traction in the region, in view of the surge in alcohol abuse, rising intake of toxic substances and overexertion. The rising availability of various categories of anti-hypertensive drugs in the region and growing access to these also promote market expansion. The growth of the antihypertensive drugs market in India can be directly linked to the rising consumption of unhealthy or junk food, lack of balanced and healthy diet, improper sleep owing to irregular working hours that result in hypertension. These factors have amplified the rate of diseases like stroke, heart failure, chronic kidney disease, peripheral vascular disease and more.


Competitive Landscape


Significant Investments by Players to Intensify Competition


Anti-hypertensive drugs industry is quite stable, since it is rife with several affluent firms. The expected market growth rate is sluggish owing to the rising use of generic drugs. Substantial spending by leading manufacturers in developing new drugs and medicines is a major trend that can continue throughout the review period. Prominent growth strategies that are primarily employed by the top vendors in the market include agreement, product launch, acquisition, expansion and partnership.


Merck is an eminent antihypertensive drug brand that aims to produce medicines as well as vaccines for highly challenging disorders. The company is known for its commitment to the global population’s health by enabling patients to have access to advanced healthcare via far-reaching programs, policies, and partnerships. Merck has also always been at the forefront of extensive researches for preventing and treatment of various diseases, which also include hypertensive disorders.


List of Key Companies Covered in this Report



  • Sanofi S.A.

  • Takeda Pharmaceuticals Company Limited

  • Boehringer Ingelheim

  • Novartis AG

  • Pfizer Inc.

  • Ranbaxy Laboratories Limited Inc.

  • Daiichi Sankyo Company Limited

  • Astra Zeneca plc

  • Acetelion Ltd


Recent Developments



  • December 2020 – Quantum Genomics, a biotech firm with expertise in class of drugs that address difficult-to-treat hypertension and heart failure, signed a contract with Delpharm, for manufacturing of its upcoming clinical range of firibastat tablets.



  • June 2020JB Chemicals and Pharmaceuticals Ltd, a well-known vendor specializing in Calcium Channel Blockers ranges for hypertension management, has launched its latest CCB in India called Azelnidipine, under the brand name Azovas. The drug is expected to be quite useful for Diabetologists, Physicians and Cardiologists for managing hypertension.


Report Overview


Scope of the Report


The scope of the report highlights drivers, opportunities, restraints and challenges surrounding the global market. With easy-to-comprehend segmentation that includes antihypertensive drugs classification, therapeutic class, distribution channel, as well as region, MRFR projections are on the basis of historical as well as expected trends. Major firms active in the global market have been profiled as well, paired with the top strategies employed by them to remain competitive in the industry.


Segmentation Table


Therapeutic Class



  • Calcium Channel Blockers

  • Beta-adrenergic Blockers

  • Renin Inhibitors

  • ACE Inhibitors

  • Vasodilators

  • Diuretics

  • ARBs

  • Others


Type



  • Primary Hypertension

  • Secondary Hypertension


Distribution Channel



  • E-commerce Websites & Online Drug Stores

  • Retail Pharmacy

  • Hospital Pharmacy

  • Others



Frequently Asked Questions (FAQ) :


Antihypertensive Drugs Market can grow up to a valuation of USD 41,123.2 million by 2023.

Antihypertensive Drugs Market would grow with a valuation of 2.67% CAGR during the forecast period of 2018 to 2023.

Antihypertensive Drugs Market has distribution channels like retail pharmacy, hospital pharmacy, e-commerce websites and online drug stores, and others.

Americas has a maximum Antihypertensive Drug Market growth.

Long-term high blood pressure is the primary antihypertensive drugs, market driver.

Global Antihypertensive Drugs Market - Summary


Overview:


Antihypertensive drugs are a class of chemicals capable of lowering high blood pressure or hypertension. Antihypertensive treatment recommended by clinicians and doctors include antihypertensive drugs which can reduce the probability of stroke and myocardial infarction. Different classes of these drugs include beta blockers, angiotensin receptor II antagonists (ARBs), ACE inhibitors, calcium channel blockers, and thiazide diuretics.


Increasing cases of hypertension is the primary driver of the antihypertensive drugs market. This is supported by data provided by the World Health Organization (WHO) which has witnessed the incidence of high blood pressure in the number of adults above the age of 22 to shoot up considerably. Awareness campaigns by government and non-government organizations can net the antihypertensive drugs market much-needed support.


High prevalence of chronic diseases is expected to spike up the production of antihypertensive drugs. According the Centers for Disease Control and Prevention (CDC), nearly 1 in 3 U.S. adults have high blood pressure. Launch of generic versions of patented drugs is likely to fuel the market growth. This is expected to lower the patient treatment costs of high blood pressure and augur well for the antihypertensive drugs market.


Segmentation:


Type-wise, the antihypertensive drugs market is segmented into primary and secondary hypertension. Primary hypertension accounted for a large share of the market in 2017 owing to genetic factors, insulin resistance, and sedentary lifestyle. Secondary hypertension accounted for a smaller market share in the same year. This percentage can fluctuate owing to consumption of cocaine, endocrine disorders, and vascular disorders.


By therapeutic class, the market is segmented into vasodilators, ACE inhibitors, renin inhibitors, diuretics, ARBs, beta-adrenergic blockers, calcium blockers, and others. Diuretics was the leading drug in the antihypertensive drugs market and indicated by maximum number of clinicians for treating hypertension. But ACE inhibitors are expected to grow exponentially owing to the ability of the drug to dilate blood vessels and lower the blood pressure. In addition, ARBs can contribute to market revenue owing to being recommended for hypertension treatment for adults above 55.


Distribution channels in the antihypertensive drugs market include hospital pharmacy, online pharmacy, e-commerce websites & online drug stores, and others. Retail pharmacy accounted for the lion’s share of the market in 2017. This can be due to setups of pharmacy outlets at ideal locations. But the segment can lose its position to e-commerce websites & online stores by 2023. This can be attributed to its customer-first model and adoption of digitization which cater to demands of patients.


Regional Analysis:


The antihypertensive drugs market covers growth drivers in the following regions, namely Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA). The Americas accounted for a large market share owing to high prevalence of hypertension linked to cardiovascular and renal disorders. Drives by government and non-government organizations for creating awareness of the medical condition are likely to bolster the revenue of the antihypertensive drugs market in Americas.


The Europe region was the second-largest due to rise of cardiovascular diseases, unhealthy diets, and increase noticed in obesity levels of patients. According to the European Heart Network in 2017, heart diseases accounted for 3.9 million deaths. Germany, France, and the U.K. are expected to be the prime contributors to the antihypertensive drugs market in Europe.


The APAC region is projected to exhibit a robust pace owing to increased healthcare budget and rise in disposable income levels of patients. The setup of research and development centers to fast-track the commoditization of drugs for treating hypertension is likely to boost the APAC antihypertensive drugs market.


Competitive Analysis:


Prominent players to get profiled in the antihypertensive drugs market report are United Therapeutics Corporation (U.S.), AstraZeneca (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Takeda Pharmaceutical Company (Japan), Sanofi S.A. (France), Merck KGaA (Germany), and Bayer AG (Germany).


 

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 17

3.2 Scope of the Study 17

3.3 List of Assumptions 17

3.4 Market Structure 18

4 Research Methodology

4.1 Research Process 20

4.2 Primary Research 20

4.3 Secondary Research 21

4.4 Market Size Estimation 22

4.5 Forecast Model 22

5 Market Dynamics

5.1 Overview 24

5.2 Drivers 24

5.2.1 Rising prevalence of hypertension 24

5.2.2 Growing initiatives by private and government organizations 24

5.2.3 Rise in the prevalence rates of chronic diseases 25

5.2.4 Increasing penetration of generic versions of drugs 25

5.3 Restraints 25

5.3.1 Side-effects of treatment options 25

5.3.2 High cost of treatment 25

5.3.3 Loss of patents 25

5.3.4 Rise in non-pharmacological therapy 25

5.4 Opportunity 26

5.4.1 Emerging therapies in the treatment hypertension 26

6 Market Factor Analysis

6.1 Value chain analysis 28

6.1.1 R&D and Designing 28

6.1.2 Manufacturing 28

6.1.3 Distribution & Sales 28

6.1.4 Post Sales Review 28

6.2 Porter’s Five Forces Model 29

6.2.1 Bargaining Power of Suppliers 29

6.2.1 Bargaining Power of Buyers 30

6.2.2 Threat of New Entrants 30

6.2.3 Threat of Substitutes 30

6.2.4 Intense Rivalry 30

6.3 Investment Opportunities 30

6.4 Pricing Analysis 31

7 Antihypertensive Drugs Market, by Therapeutic Class

7.1 Overview 33

7.2 Diuretics 34

7.3 ACE Inhibitors 35

7.4 ARBs 36

7.5 Calcium Channel Blockers 37

7.6 Beta-Adrenergic Blockers 38

7.7 Renin Inhibitors 39

7.8 Vasodilators 39

7.9 Others 40

8 Antihypertensive Drugs Market, by Type

8.1 Overview 42

8.2 Primary Hypertension 43

8.3 Secondary Hypertension 44

9 Antihypertensive Drugs Market, by Distribution Channel

9.1 Overview 46

9.2 Retail Pharmacy 47

9.3 Hospital Pharmacy 47

9.4 E-commerce Websites & Online Drug Stores 48

9.5 Others 48

10 Global Antihypertensive Drugs Market, by Region

10.1 Overview 50

10.2 Americas 51

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.2.1 North America 53

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.2.1.1 US 56

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.2.1.2 Canada 57

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.2.2 Latin America 59

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3 Europe 61

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1 Western Europe 63

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.1 Germany 66

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.2 France 67

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.3 UK 69

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.4 Italy 70

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.5 Spain 72

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.1.6 Rest of Western Europe 73

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.3.2 Eastern Europe 75

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4 Asia-Pacific 77

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.1 Japan 79

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.2 China 81

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.3 India 82

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.4 Australia 84

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.5 South Korea 85

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.4.6 Rest of Asia-Pacific 87

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.5 Middle East & Africa 89

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.5.1 Middle East 91

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

10.5.2 Africa 93

Antihypertensive Drugs Market, by Therapeutic Class

Antihypertensive Drugs Market, by Type

Antihypertensive Drugs Market, by Distribution Channel

11 Competitive Landscape

11.1 Overview 96

11.2 Company Share Analysis 96

12 Company Profile

12.1 Sanofi S. A. 99

12.1.1 Company Overview 99

12.1.2 Financial Overview 99

12.1.3 Products Offered 100

12.1.4 SWOT Analysis 100

12.1.5 Key Developments 100

12.1.6 Key strategy 100

12.2 Novartis AG 101

12.2.1 Company Overview 101

12.2.2 Financial Overview 101

12.2.3 Products Offered 102

12.2.4 SWOT Analysis 102

12.2.5 Key Developments 102

12.2.6 Key strategy 102

12.3 AstraZeneca 103

12.3.1 Company Overview 103

12.3.2 Financial Overview 103

12.3.3 Products Offered 104

12.3.4 SWOT Analysis 104

12.3.5 Key Developments 104

12.3.6 Key strategy 104

12.4 Daiichi Sankyo Company, Ltd 105

12.4.1 Company Overview 105

12.4.2 Financial Overview 105

12.4.3 Products Offered 106

12.4.4 SWOT Analysis 106

12.4.5 Key Developments 106

12.4.6 Key Strategy 106

12.5 Boehringer Ingelheim GmbH 107

12.5.1 Company Overview 107

12.5.2 Financial Overview 107

12.5.3 Products Offered 108

12.5.4 SWOT Analysis 108

12.5.5 Key Developments 108

12.5.6 Key Strategy 108

12.6 Takeda Pharmaceutical Company Ltd 109

12.6.1 Company Overview 109

12.6.2 Financial Overview 109

12.6.3 Products Offered 109

12.6.4 SWOT Analysis 110

12.6.5 Key Developments 110

12.6.6 Key Strategy 110

12.7 Merck KGaA 111

12.7.1 Company Overview 111

12.7.2 Financial Overview 111

12.7.3 Products Offered 111

12.7.4 SWOT Analysis 112

12.7.5 Key Developments 112

12.7.6 Key Strategy 112

12.8 Johnson & Johnson Services, Inc. 113

12.8.1 Company Overview 113

12.8.2 Financial Overview 113

12.8.3 Products Offered 114

12.8.4 SWOT Analysis 114

12.8.5 Key Developments 114

12.8.6 Key Strategy 114

12.9 Bayer AG 115

12.9.1 Company Overview 115

12.9.2 Financial Overview 115

12.9.3 Products Offered 115

12.9.4 SWOT Analysis 116

12.9.5 Key Developments 116

12.9.6 Key Strategy 116

12.10 Pfizer, Inc. 117

12.10.1 Company Overview 117

12.10.2 Financial Overview 117

12.10.3 Products Offered 118

12.10.4 SWOT Analysis 118

12.10.5 Key Developments 118

12.10.6 Key Strategy 118

12.11 United Therapeutics Corporation 119

12.11.1 Company Overview 119

12.11.2 Financial Overview 119

12.11.3 Products Offered 120

12.11.4 SWOT Analysis 120

12.11.5 Key Developments 120

12.11.6 Key Strategy 120

13 Appendix

13.1 Discussion Blue Print 122

14 List of Tables

TABLE 1 MARKET SYNOPSIS 15

TABLE 2 LIST OF ASSUMPTIONS 17

TABLE 3 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 33

TABLE 4 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR DIURETICS, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 5 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR ACE INHIBITORS, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 6 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR ARBS, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 7 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR CALCIUM CHANNEL BLOCKERS, BY REGION, 2020–2027 (USD MILLION) 37

TABLE 8 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR BETA-ADRENERGIC BLOCKERS, BY REGION, 2020–2027 (USD MILLION) 38

TABLE 9 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR RENIN INHIBITORS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 10 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR VASODILATORS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 11 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 42

TABLE 12 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR PRIMARY HYPERTENSION, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 13 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR SECONDARY HYPERTENSION, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 14 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 46

TABLE 15 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR RETAIL PHARMACY, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 16 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2020–2027 (USD MILLION) 47

TABLE 17 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET FOR E-COMMERCE WEBSITES AND ONLINE DRUG STORES, BY REGION, 2020–2027 (USD MILLION) 48

TABLE 18 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 50

TABLE 19 AMERICAS: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 51

TABLE 20 AMERICAS: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 52

TABLE 21 AMERICAS: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 22 AMERICAS: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 53

TABLE 23 NORTH AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

TABLE 24 NORTH AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 54

TABLE 25 NORTH AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

TABLE 26 NORTH AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 55

TABLE 27 US: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 56

TABLE 28 US: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 29 US: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 57

TABLE 30 CANADA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 57

TABLE 31 CANADA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 32 CANADA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 58

TABLE 33 LATIN AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 59

TABLE 34 LATIN AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 35 LATIN AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 60

TABLE 36 EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 37 EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 62

TABLE 38 EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 39 EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 63

TABLE 40 WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 41 WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 64

TABLE 42 WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

TABLE 43 WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 65

TABLE 44 GERMANY: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 66

TABLE 45 GERMANY: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 46 GERMANY: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 67

TABLE 47 FRANCE: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 67

TABLE 48 FRANCE: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 49 FRANCE: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 68

TABLE 50 UK: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 69

TABLE 51 UK: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 52 UK: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 70

TABLE 53 ITALY: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 70

TABLE 54 ITALY: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 55 ITALY: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 71

TABLE 56 SPAIN: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 72

TABLE 57 SPAIN: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 58 SPAIN: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 73

TABLE 59 REST OF WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 73

TABLE 60 REST OF WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 61 REST OF WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 74

TABLE 62 EASTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 75

TABLE 63 EASTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

TABLE 64 EASTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 76

TABLE 65 ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77

TABLE 66 ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 78

TABLE 67 ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 68 ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 79

TABLE 69 JAPAN: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 79

TABLE 70 JAPAN: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

TABLE 71 JAPAN: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 80

TABLE 72 CHINA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 81

TABLE 73 CHINA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 74 CHINA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 82

TABLE 75 INDIA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 82

TABLE 76 INDIA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 77 INDIA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 83

TABLE 78 AUSTRALIA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 84

TABLE 79 AUSTRALIA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 80 AUSTRALIA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 85

TABLE 81 SOUTH KOREA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 85

TABLE 82 SOUTH KOREA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

TABLE 83 SOUTH KOREA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 86

TABLE 84 REST OF ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 87

TABLE 85 REST OF ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

TABLE 86 REST OF ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 88

TABLE 87 MIDDLE EAST & AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020–2027 (USD MILLION) 89

TABLE 88 MIDDLE EAST & AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 90

TABLE 89 MIDDLE EAST & AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 90 MIDDLE EAST & AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 91

TABLE 91 MIDDLE EAST: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 91

TABLE 92 MIDDLE EAST: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

TABLE 93 MIDDLE EAST: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 92

TABLE 94 AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2027 (USD MILLION) 93

TABLE 95 AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 96 AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2027 (USD MILLION) 94


15 List of Figures

FIGURE 1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: MARKET STRUCTURE 18

FIGURE 2 RESEARCH PROCESS OF MRFR 20

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACHES 22

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ANTIHYPERTENSIVE DRUGS MARKET 24

FIGURE 5 VALUE CHAIN: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET 28

FIGURE 6 PORTER’S FIVE FORCES ANALYSIS: GLOBAL ANTIHYPERTENSIVE DRUGS MARKET 29

FIGURE 7 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY THERAPEUTIC CLASS, 2020 AND 2027 (USD MILLION) 33

FIGURE 8 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY TYPE, 2020 AND 2027 (USD MILLION) 42

FIGURE 9 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020 AND 2027 (USD MILLION) 46

FIGURE 10 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020 AND 2027 (USD MILLION) 50

FIGURE 11 AMERICAS: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020 (%) 51

FIGURE 12 NORTH AMERICA: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020 (%) 53

FIGURE 13 EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020 (%) 61

FIGURE 14 WESTERN EUROPE: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020 (%) 63

FIGURE 15 ASIA-PACIFIC: ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2020 (%) 77

FIGURE 16 MIDDLE EAST & AFRICA: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2020 (%) 89

FIGURE 17 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET: COMPANY SHARE ANALYSIS, 2020 (%) 96

Global Antihypertensive Drugs Market: Company Landscape


There are numerous large and small players operating in the global antihypertensive drugs market. Owing to the loss of patents of major branded antihypertensive drugs in the recent years, many players have entered into the market with generic drugs which has led to the significant loss of market share of major players operating in the market.


Some prominent players in the global antihypertensive drugs market are Novartis AG, United Therapeutics Corporation, Daiichi Sankyo Company, Ltd, Sanofi, Bayer AG, Boehringer Ingelheim GmbH, AstraZeneca Plc among others.


Novartis AG is one of the leading players in the global antihypertensive drugs market. The share of the company is due to its antihypertensive its products Diovan/Co-Diovan and Exforge. The company’s share was affected by the high genericization of its antihypertensive drugs. Novartis AG has strong brand name along with extensive global presence. The company is currently focusing in development of new products to increase its revenue generation. Moreover, the company is also engaged in strategic collaborations and mergers to strengthen its position in the pharmaceutical segment.


United Therapeutics Corporation is one of the prominent players in the global antihypertensive drugs market. The company has decent product portfolio for pulmonary arterial hypertension (PAH). United Therapeutics Corporation has strong market penetration in the US market. The company has increased its focus on expanding its business in the international market.


Daiichi Sankyo Company, Ltd, a renowned company in the global antihypertensive drugs market, is engaged in strategic merger activities which has helped in strengthening its brand image. The company is involved in developing new drugs for treating hypertension which is expected to increase its market revenue in the coming years. For instance, in September 2017, the company announced that the Phase 3 study for Esaxerenone for treatment of essential hypertension in Japan was successful and showed positive outcomes.


Apart from these companies, there are large number of companies operating in this market. The other players include Hikma Pharmaceuticals, Amneal Pharmaceuticals LLC, Upsher-Smith Laboratories, LLC, Apotex Corporation, Aa Pharma Inc., Salix Pharmaceuticals, Ipca Laboratories Limited, Ranbaxy Inc., Macleods Pharmaceuticals Limited, Jamp Pharma Corporation, Wockhardt USA LLC., and Glenmark Pharmaceuticals Inc.